tiprankstipranks
InMed Pharmaceuticals Faces Nasdaq Delisting Challenge
Company Announcements

InMed Pharmaceuticals Faces Nasdaq Delisting Challenge

Pick the best stocks and maximize your portfolio:

InMed Pharmaceuticals ( (INM) ) just unveiled an update.

InMed Pharmaceuticals Inc. is facing potential delisting from the Nasdaq Capital Market for not meeting the minimum bid price requirement. The company has appealed this decision and has been granted a hearing with the Nasdaq Listing Qualifications Panel, scheduled for October 31, 2024. In the meantime, the appeal has postponed any delisting actions. The outcome of the hearing is uncertain, and there’s no assurance given that the company will be granted an extension to meet Nasdaq’s compliance requirements.

For detailed information about INM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskInMed Pharmaceuticals’ 2024 AGM Results Announced
TipRanks Canadian Auto-Generated NewsdeskInMed Pharmaceuticals Secures $10 Million Equity Purchase Agreement
TipRanks Auto-Generated NewsdeskInMed Pharmaceuticals Explores CBN for Skin Disease Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App